BioLife Solutions (NASDAQ:BLFS) Director Amy Duross Sells 2,000 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) Director Amy Duross sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $24.60, for a total transaction of $49,200.00. Following the transaction, the director directly owned 18,687 shares of the company’s stock, valued at $459,700.20. This trade represents a 9.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Amy Duross also recently made the following trade(s):

• On Tuesday, November 25th, Amy Duross sold 2,000 shares of BioLife Solutions stock. The stock was sold at an average price of $27.00, for a total transaction of $54,000.00.
• On Friday, November 21st, Amy Duross sold 1,000 shares of BioLife Solutions stock. The shares were sold at an average price of $26.00, for a total transaction of $26,000.00.
• On Thursday, November 20th, Amy Duross sold 4,523 shares of BioLife Solutions stock. The shares were sold at an average price of $24.51, for a total value of $110,858.73.
• On Wednesday, November 19th, Amy Duross sold 477 shares of BioLife Solutions stock. The shares were sold at an average price of $24.50, for a total value of $11,686.50.

BioLife Solutions Trading Up 2.7%

Shares of BLFS traded up $0.68 during midday trading on Thursday, reaching $25.69. 53,084 shares of the company were exchanged, compared to its average volume of 443,760. BioLife Solutions, Inc. has a 1-year low of $19.10 and a 1-year high of $29.62. The stock has a 50-day moving average price of $26.34 and a 200-day moving average price of $24.52. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -368.03 and a beta of 1.93.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BLFS. T. Rowe Price Investment Management Inc. acquired a new stake in shares of BioLife Solutions during the first quarter valued at approximately $30,789,000. Royal Bank of Canada raised its stake in BioLife Solutions by 762.8% during the 1st quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider’s stock valued at $15,948,000 after purchasing an additional 617,320 shares during the period. Qube Research & Technologies Ltd lifted its holdings in shares of BioLife Solutions by 2,399.5% in the second quarter. Qube Research & Technologies Ltd now owns 248,474 shares of the medical equipment provider’s stock valued at $5,352,000 after purchasing an additional 238,533 shares in the last quarter. Summit Creek Advisors LLC purchased a new stake in shares of BioLife Solutions in the third quarter valued at $4,905,000. Finally, Mutual of America Capital Management LLC boosted its position in shares of BioLife Solutions by 22.2% in the second quarter. Mutual of America Capital Management LLC now owns 638,373 shares of the medical equipment provider’s stock worth $13,751,000 after buying an additional 115,963 shares during the period. 93.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BLFS has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $32.00 price objective on shares of BioLife Solutions in a research note on Monday, November 24th. Wall Street Zen lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating in a report on Sunday, November 30th. Finally, Zacks Research downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 8th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $30.75.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.